BioXcell Initiates European/Asian Marketing Campaign at ESHRE for INVOcell Infertility Treatment; Aims to Help More than 100 Million Couples Worldwide Suffering From Infertility

At the just-concluded European Society of Human Reproduction and Embryology (ESHRE) annual conference in Barcelona, BioXCell (http://www.bioxcell.com) reports enthusiastic reception of its INVOcell infertility treatment.

According to Rusty Warren, Ph.D., Chief Executive Officer of BioXcell, "Reaching the more than 100 million worldwide couples suffering from infertility is the goal of over two dozen international marketing organizations already expressing interest in representing BioXcell and INVOcell. We recently received a CE Mark, the European equivalent to approval by the Food and Drug Administration (FDA) in the U.S."

Sean Paradis, BioXcell Vice President, and Director of Sales and Marketing, said, "We are encouraged that leading distributors in the healthcare industry across Europe and Asia are making INVOcell available. BioXcell has a clear and focused sales and marketing strategy moving forward that will ensure the long term success of the INVOcell. Infertility patients are long overdue for a procedure and product that makes sense.

"INVOcell allows conception and embryo development to take place inside the woman's body, making having a baby simpler and less expensive, while promoting involvement by the woman," Mr. Paradis added.

Claude Ranoux, MD, President and Chief Scientist of BioXcell, explained, "The INVO procedure uses a lower stimulation approach to produce eggs for fertilization. Eggs are combined with sperm in the INVOcell device and placed in the woman's vaginal cavity where it remains for 3 days. This step eliminates the need for a complex IVF laboratory and allows the woman's body to provide the nurturing environment in which conception and early embryo development take place."

About ESHRE

The main aim of ESHRE is to promote interest in, and understanding of, reproductive biology and medicine. It does this through facilitating research and subsequent dissemination of research findings in human reproduction and embryology to the general public, scientists, clinicians and patient associations; it also works to inform politicians and policy makers throughout Europe.

About BioXcell, A Simpler Way To Life

BioXcell's INVOcell will revolutionize the treatment of infertility. The INVOcell replaces the IVF laboratory and allows conception to take place naturally inside the woman's body. INVO offers a new fertility treatment that can be performed successfully in the office of an infertility specialist. INVO is simple and more effective that IUI and at a lower cost per pregnancy compared to IVF. Previous worldwide studies (over 800 clinical cases) published in peer-reviewed journals have demonstrated an efficacy of this procedure to be comparable to conventional IVF. BioXcell has 5 current patents on the INVOcell device and procedure; INVOcell is manufactured in the United States. Please visit www.bioxcell.com for more information.